These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36286834)

  • 21. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
    Milovanova LY; Lysenko Kozlovskaya LV; Milovanova SY; Taranova MV; Kozlov VV; Reshetnikov VA; Lebedeva MV; Androsova TV; Zubacheva DO; Chebotareva NV
    Ter Arkh; 2020 Jul; 92(6):37-45. PubMed ID: 33346491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
    Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
    J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.
    Krajisnik T; Olauson H; Mirza MA; Hellman P; Akerström G; Westin G; Larsson TE; Björklund P
    Kidney Int; 2010 Nov; 78(10):1024-32. PubMed ID: 20686451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.
    Lim K; Lu TS; Molostvov G; Lee C; Lam FT; Zehnder D; Hsiao LL
    Circulation; 2012 May; 125(18):2243-55. PubMed ID: 22492635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5.
    Schön A; Leifheit-Nestler M; Deppe J; Fischer DC; Bayazit AK; Obrycki L; Canpolat N; Bulut IK; Azukaitis K; Yilmaz A; Mir S; Yalcinkaya F; Soylemezoglu O; Melk A; Stangl GI; Behnisch R; Shroff R; Bacchetta J; Querfeld U; Schaefer F; Haffner D;
    Nephrol Dial Transplant; 2021 Feb; 36(3):442-451. PubMed ID: 33241290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The FGF-23/klotho axis and its relationship with phosphorus, calcium, vitamin D, PTH, aldosterone, severity of disease, and outcome in hospitalised foals.
    Kamr AM; Dembek KA; Hildreth BE; Morresey PR; Rathgeber RA; Burns TA; Zaghawa AA; Toribio RE
    Equine Vet J; 2018 Nov; 50(6):739-746. PubMed ID: 29660161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
    Liu QF; Ye JM; Yu LX; He AL; Sun Q; He DW; Li SS
    J Investig Med; 2018 Mar; 66(3):669-675. PubMed ID: 29061648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease.
    Sueta S; Morozumi K; Takeda A; Horike K; Otsuka Y; Shinjo H; Murata M; Kato Y; Goto K; Inaguma D;
    Clin Exp Nephrol; 2015 Jun; 19(3):371-8. PubMed ID: 24916005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of vitamin D receptor activator therapy on vitamin D receptor and osteocalcin expression in circulating endothelial progenitor cells of hemodialysis patients.
    Cianciolo G; La Manna G; Della Bella E; Cappuccilli ML; Angelini ML; Dormi A; Capelli I; Laterza C; Costa R; Alviano F; Donati G; Ronco C; Stefoni S
    Blood Purif; 2013; 35(1-3):187-95. PubMed ID: 23485859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fgf23 and parathyroid hormone signaling interact in kidney and bone.
    Andrukhova O; Streicher C; Zeitz U; Erben RG
    Mol Cell Endocrinol; 2016 Nov; 436():224-39. PubMed ID: 27498418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism.
    Negri AL; Brandenburg VM
    Int Urol Nephrol; 2014 Jun; 46(6):1145-51. PubMed ID: 24384877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.
    ; Shoji T; Inaba M; Fukagawa M; Ando R; Emoto M; Fujii H; Fujimori A; Fukui M; Hase H; Hashimoto T; Hirakata H; Honda H; Hosoya T; Ikari Y; Inaguma D; Inoue T; Isaka Y; Iseki K; Ishimura E; Itami N; Ito C; Kakuta T; Kawai T; Kawanishi H; Kobayashi S; Kumagai J; Maekawa K; Masakane I; Minakuchi J; Mitsuiki K; Mizuguchi T; Morimoto S; Murohara T; Nakatani T; Negi S; Nishi S; Nishikawa M; Ogawa T; Ohta K; Ohtake T; Okamura M; Okuno S; Shigematsu T; Sugimoto T; Suzuki M; Tahara H; Takemoto Y; Tanaka K; Tominaga Y; Tsubakihara Y; Tsujimoto Y; Tsuruya K; Ueda S; Watanabe Y; Yamagata K; Yamakawa T; Yano S; Yokoyama K; Yorioka N; Yoshiyama M; Nishizawa Y
    JAMA; 2018 Dec; 320(22):2325-2334. PubMed ID: 30535217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
    Jean G; Souberbielle JC; Chazot C
    Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.